Search

… diseases, announced today that its sepofarsen (QR-110) drug candidate, which is being developed for targeting the … the PRIME program provides a framework for enhancing our development plans by working closely with the EMA.” The EMA … the risks and uncertainties inherently associated with drug development, including that any one or more of our …

… Robert Friesen to Senior Vice President Science and Early Development. David M. Rodman, M.D., Chief Development … in March 2017 with extensive experience in rare disease drug development, translational medicine and RNA …

… ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan … are no therapies commercially available or in clinical development for the vision loss associated with this disease. … oligonucleotide drug discovery platform with accelerated drug development strategies for rare diseases.  Orphan drug …

… ProQR. “With this transaction we’ve now fully focused our development pipeline on the ophthalmology programs in pursuit … again with Hal and the EBRP to apply our experience in DEB drug development to develop transformational therapies for …

… Advisory Board that will play a strategic role in the development of the Company’s pipeline. The Scientific … Levin PhD , has more than two decades of experience in RNA drug development from discovery through drug registration, …

… Ph.D., has more than two decades of experience in RNA drug development from discovery through drug registration, …

… delivery data, and an update on preparation for clinical development to be provided for QR-313. M. Peter Marinkovich, … Boer.  “The invention and patenting of Axiomer® can drive drug discovery and development of a new class of … Board. Dr. Levin has three decades of experience in RNA drug development from discovery through drug registration, …

… biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of … patient advocacy organization that supports select CF drug development programs by providing financial support and …

… of ProQR. "We have advanced QR-010 through preclinical development and are looking forward to starting the clinical … patient advocacy organization that supports select CF drug development programs by providing financial support and …

… continue to make good progress with our three different development programs, all RNA oligonucleotides for serious … with LCA10 due to the p.Cys998X mutation received orphan drug designation (ODD) from both the U.S. Food and Drug … We believe that James’ broad knowledge and expertise in drug development and pharma will be of significant value to …